Print

IGBA Statement // Solidarity Call to Action: To realize equitable global access to COVID-19 health technologies through sharing of knowledge, intellectual property and data (29 May 2020)

“The International Generic and Biosimilar medicines Association (IGBA) invites generic and biosimilar medicines manufacturers to actively engage and commit to contributing to the global manufacturing capacity once an existing or newly-discovered therapeutic is proven to be effective against COVID-19.

Print

IGBA Pays Tribute to Bill Haddad (4 May 2020)

IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today pays tribute to Bill Haddadi, who passed away last week. He was a pioneer in the development of generic medicine policy in the U.S.A. and a remarkable advocate for access to medicines worldwide.

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

Telephone: +32 (0)2 5346607 (S. Kox)
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site